Key result
Medical therapy increasingly manages heart failure in DMD as improved care extends patient survival.
Why the study?
Improved skeletal muscle and respiratory care have prolonged survival in Duchenne muscular dystrophy, resulting in a greater proportion of patients experiencing heart failure and cardiac-related mortality.
Provides a review of current indications for cardiac medical therapy in patients with Duchenne muscular dystrophy, a population increasingly experiencing heart failure due to longer survival.
May support HF therapy consideration in longer-surviving DMD patients; leaves open optimal regimens for prospective trials.
There have been significant improvements in the skeletal muscle and respiratory care for patients with Duchenne muscular dystrophy (DMD) over the last two decades. This has resulted in longer expected survival as many patients will live into their 20s and 30s. This timeline has resulted in a greater proportion of patients experiencing heart failure and cardiac-related mortality. Herein, we describe the current indications for medical therapy for patients with DMD.
No takes yet. Share an insight, caveat, or question.
Wittekind et al. (2021) conducted a review in Duchenne muscular dystrophy. Medical therapy was evaluated. Medical therapy for patients with Duchenne muscular dystrophy is increasingly indicated to manage heart failure as improved care extends patient survival into their 20s and 30s.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: